Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TNXP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTonix presents Phase 1 data for Lyme disease candidate TNX-4800, targets Phase 2 trial in H1 2027
Filed May 15, 2026 · Period ending May 15, 2026 · ~1 min read
Key Changes
-
high
Pharmacokinetic simulations show two-dose regimen maintains therapeutic levels above 10 µg/mL for 196 days, supporting six-month protection endpoint for planned Phase 2 field study.
Item 8.01 verify on EDGAR → -
high
Company plans adaptive Phase 2 field study for TNX-4800 in first half of 2027, pending FDA agreement on trial design and endpoints.
Item 8.01 verify on EDGAR → -
medium
Phase 1 trial data for TNX-4800, a monoclonal antibody Lyme disease prevention candidate, presented at Global Lyme Alliance conference on May 15, 2026.
Item 8.01 verify on EDGAR →
Summary
Tonix Pharmaceuticals disclosed promising Phase 1 pharmacokinetic data for TNX-4800, its monoclonal antibody candidate designed to prevent Lyme disease. The company presented simulation results showing that a two-dose regimen (350 mg subcutaneous injections on Day 1 and Day 56) can maintain therapeutic serum levels above the key 10 µg/mL threshold for 196 days—supporting a six-month protection window.
This data validates the feasibility of the proposed primary endpoint for the upcoming Phase 2 field study. For retail investors, this represents meaningful progress in Tonix's clinical pipeline. The company is targeting a Phase 2 field study launch in the first half of 2027, though this remains contingent on FDA agreement.
Lyme disease affects an estimated 476,000 Americans annually, representing a significant commercial opportunity if TNX-4800 proves effective in real-world prevention. Watch for FDA feedback on the Phase 2 trial design in coming months. Positive regulatory alignment would clear the path for the pivotal field study and potentially accelerate the timeline to market for this first-in-class prevention approach.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 15, 2026, Tonix Pharmaceuticals Holding Corp. (the “Company”) presented certain data from the Phase 1 trial for its TNX-4800 product candidate for protection against Lyme disease at the Global Lyme Alliance.
The company publicly disclosed Phase 1 clinical trial data for TNX-4800, a product candidate designed to protect against Lyme disease, at a Global Lyme Alliance event. The presentation materials are attached as an exhibit to this filing. This represents a milestone in the drug development process, though the 8-K does not summarize the actual trial results or efficacy data.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 15, 2026, the Company presented the following analysis of pharmacokinetic data from the Phase 1 trial for TNX-4800 at the Global Lyme Alliance in connection with the proposed adaptive Phase 2 field study for TNX-4800, planned for the first half of 2027, pending agreement by the U.S. Food and Drug Administration
Tonix publicly presented pharmacokinetic analysis from its Phase 1 trial of TNX-4800, a Lyme disease treatment candidate, at the Global Lyme Alliance conference. The presentation relates to a planned adaptive Phase 2 field study targeted for the first half of 2027, which is still pending FDA agreement.
Added in current filing · verify on EDGAR →
Simulation of a two-dose regimen (350 mg subcutaneous administration on Day 1 and 56 Days) of TNX-4800 were presented that predict mean serum levels for participants in the field study. Predictions were quantified for the time in days for serum levels to decrease below four serum levels, referred to as Minimum Effective Concentrations (“MECs”), of 10 µg/mL , 15 µg/mL, 20 µg/mL and 5 µg/mL. Days to MEC were: MEC1 (10 µg/mL): 196 days; MEC2 (15 µg/mL): 161 days; MEC3 (20 µg/mL): 136 days; MEC4 (5 µg/mL): 265 days.
The company disclosed simulation data for a two-dose 350 mg subcutaneous regimen administered on Day 1 and Day 56. The simulations predict how long serum levels remain above various minimum effective concentrations, with the key 10 µg/mL threshold maintained for 196 days. These data points will inform the design and endpoints of the upcoming Phase 2 field study.
Added in current filing · verify on EDGAR →
The simulations and predictions support the feasibility of a two-dose 350 mg regimen maintaining a minimal mean serum level above MEC 10 µg/mL for six months following the initial dose, the proposed primary endpoint for the field study.
The pharmacokinetic simulations demonstrate that the proposed two-dose regimen can maintain therapeutic serum levels above 10 µg/mL for six months after the initial dose. This finding supports the feasibility of the planned Phase 2 field study and defines its proposed primary endpoint, which is critical for regulatory discussions and trial design.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
TNX-4800: A Long-Acting, Bactericidal, Human Monoclonal Antibody to Prevent Lyme Disease in the U.S.
The company disclosed a presentation on TNX-4800, described as a long-acting, bactericidal, human monoclonal antibody intended to prevent Lyme disease in the United States. The 8-K itself contains no substantive details about clinical trial results, regulatory milestones, or commercial agreements related to this candidate.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify